Publications

cemka > Publications

Classer les publications sur l'année

  • Pharmaco-EpidĂ©miologie

    La mortalitĂ© observĂ©e Ă  trois ans dans l’enquĂȘte CAROLE

    JALLON P, DE ZELICOURT M, FAGNANI F, LAURENDEAU C, FAILLIOT M

    Epilepsies ; 2007;19(3):173-177

  • Pharmaco-EpidĂ©miologie

    Irritable bowel syndrome in France : quality of life, medical management, and costs : the Encoli Study

    BRUN-STRANG C, DAPOIGNY M, LAFUMA A, WAINSTEN JP, FAGNANI F

    Eur J Gastroenterol Hepatol ; 19(12):1097-1103

  • Pharmaco-EpidĂ©miologie

    Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France

    MONSONEGO J, BREUGELMANS JG, BOUEE S, LAFUMA A, BENARD S, REMY V

    Gynécol Obstét Fertil ; 35:107-113

  • Économie de la santĂ©

    Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2

    FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL

    Bulletin du Cancer ; 94(7):711-720

  • Pharmaco-EpidĂ©miologie

    Epidemiology, impact, management and cost of Paget’s disease of bone in France

    SARAUX A, BRUN-STRANG C, MIMAUD V, VIGNERON AM, LAFUMA A

    Joint Bone Spine ; 74(1):90-95

  • Économie de la santĂ©

    CoĂ»t de l’obĂ©sitĂ© en France

    EMERY C, DINET J, LAFUMA A, SERMET C, KHOSHNOOD B, FAGNANI F

    Presse Med ; 832-840

  • Économie de la santĂ©

    Invasive cervical cancer treatment costs in France

    ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG

    Bull Cancer ; 94(2):219-224

  • Économie de la santĂ©

    CoĂ»t de la prise en charge des frottis anormaux et des nĂ©oplasies intraĂ©pithĂ©liales du col de l’utĂ©rus en France

    BERGERON C, COHET C, BOUEE S, LORANS C, REMY V

    BEH ; (1):4-6

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Costs of cardiovascular events of diabetic patients in French hospitals

    COLIN X, LAFUMA A, GUERON B

    Diabetes Metab ; 2007;33(4):310-313

  • Économie de la santĂ©

    Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma : analysis conducted on the United Kingdom General Practitioner Research Database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 23(12):3009-3016

  • Économie de la santĂ©

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254

  • Économie de la santĂ©

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy

    DENIS PH, LAFUMA A, KHOSHNOOD B, MIMAUD V, BERDEAUX G

    Curr Med Res Opin ; 23(3):601-608

  • Pharmaco-EpidĂ©miologie

    A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment

    ISNARD F, TILLEUL P, LAPORTE JF, CHEVALLIER P, PIGNEUX A, LAFUMA A, MAHI L, DERAY G

    Nephrol Dial Transplant ; 22(10):3090-3091

  • SantĂ© publique

    Evaluation of a screening programme for diabetic retinopathy (DODIA study).

    AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWEGE E, JAMET M, MARRE M, NOUGAIRÈDE M, TCHERNY-LESSENOT S

    Rev Prat. ; 57(11):1203-1209